Market Cap (In GBp)
22.85 Million
Revenue (In GBp)
-
Net Income (In GBp)
-3.42 Million
Avg. Volume
604.32 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 10.0-78.0
- PE
- -5.67
- EPS
- -0.03
- Beta Value
- -0.978
- ISIN
- GB00BMC3RJ87
- CUSIP
- G78173104
- CIK
- -
- Shares
- 133488000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
- Employee Count
- -
- Website
- https://www.sareum.com
- Ipo Date
- 2004-10-11
- Details
- Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
More Stocks
-
NGL
-
AXTG
-
AXAHYAXA SA
AXAHY
-
8945SUNNEXTA GROUP Inc.
8945
-
SWUT
-
WPH
-
360ONE360 One Wam Limited
360ONE
-
RACEFerrari N.V.
RACE